Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus CORTISONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus CORTISONE ACETATE.
BREO ELLIPTA vs CORTISONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Corticosteroid with glucocorticoid and mineralocorticoid activity; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune responses.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
25-300 mg per day orally, in divided doses every 6-12 hours, depending on condition severity.
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Clinical Note
moderateCortisone acetate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Gatifloxacin."
Clinical Note
moderateCortisone acetate + Rosoxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Rosoxacin."
Clinical Note
moderateCortisone acetate + Levofloxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Levofloxacin."
Clinical Note
moderate30 minutes (plasma half-life of cortisol); biological half-life 8-12 hours (due to intracellular receptor binding and transcriptional effects)
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Renal (approximately 90% as metabolites, <5% unchanged); biliary/fecal (<5%)
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid
Cortisone acetate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Trovafloxacin."